What we're thinking about.
Technical articles, bench notes and regulatory perspectives from the Base team.
Cell permeability: aligning the experimental model with your scientific question
Permeability is not an intrinsic property of the molecule, but the result of the interaction between the molecule, the chosen model and the experimental context. The real question is not which model is correct, but which one answers what you need to know.
BRCA1 and BRCA2: what changed with SUS availability — and how your clinic can offer this test
With BRCA1 and BRCA2 widely offered by the Brazilian public health system, hereditary cancer genetic testing became public policy. Learn how your clinic can deliver the same quality standard without building its own molecular biology infrastructure.
Why cell line authentication is the silent foundation of your pipeline
Studies in high-impact journals continue to be retracted due to misidentified cell lines. Understand how the ANSI/ATCC ASN-0002 standard protects your reputation.
Analytical validation ICH Q2(R2): what changes for biologics and diagnostics
The ICH Q2 revision expands validation criteria for multivariate analytical methods and biotech products. We translate what that means at the bench.
Cell line authentication: why validating cellular identity is essential in preclinical research
Scientific reproducibility depends on a frequently underestimated factor: the authenticity of cell lines. Understand why validating cellular identity is no longer optional in preclinical research.
3D cellular models for mRNA and advanced therapies
Organoids and spheroids are no longer academic experiments. For complex therapeutic modalities they are the only practical way to generate predictive data.
How to analyze cell signaling pathways in in vitro assays: experimental strategies and applications in preclinical research
Experimental strategies to monitor cellular activation, characterize mechanisms of action and validate molecular targets in in vitro cell assays.
How a scientific boutique serves global clients without losing depth
Scale is not the same as capacity. We explain the operating model that lets us deliver in 6–12 weeks for clients in Europe, the US and Asia.
HPV-DNA in Brazil in 2026: global evolution, the advance of self-collection and the next steps
The HPV-DNA molecular test has become the gold standard in cervical cancer screening. Understand the global evolution, the advance of self-collection and the role of specialized laboratories in Brazil.
HPV-DNA testing: a practical implementation guide to add value and precision to your clinic
In a healthcare market increasingly driven by precision, HPV-DNA testing is no longer an innovation but an essential component of preventive care — and implementing it is a decision about value, loyalty and competitive differentiation.